opc-67683 and Hepatitis-C

opc-67683 has been researched along with Hepatitis-C* in 1 studies

Other Studies

1 other study(ies) available for opc-67683 and Hepatitis-C

Article	Year
Six-Month Response to Delamanid Treatment in MDR TB Patients. Emerging infectious diseases, 2017, Volume: 23, Issue:10 Delamanid, recently available for the treatment of multidrug-resistant tuberculosis (MDR TB), has had limited use outside clinical trials. We present the early treatment results for 53 patients from 7 countries who received a delamanid-containing treatment for MDR TB. Results show good tolerability and treatment response at 6 months. Topics: Adolescent; Antitubercular Agents; Female; Hepatitis C; HIV Infections; Humans; Male; Nitroimidazoles; Oxazoles; Retrospective Studies; Tuberculosis, Multidrug-Resistant	2017

Article

Year

Six-Month Response to Delamanid Treatment in MDR TB Patients.

Emerging infectious diseases, 2017, Volume: 23, Issue:10

Delamanid, recently available for the treatment of multidrug-resistant tuberculosis (MDR TB), has had limited use outside clinical trials. We present the early treatment results for 53 patients from 7 countries who received a delamanid-containing treatment for MDR TB. Results show good tolerability and treatment response at 6 months.

Topics: Adolescent; Antitubercular Agents; Female; Hepatitis C; HIV Infections; Humans; Male; Nitroimidazoles; Oxazoles; Retrospective Studies; Tuberculosis, Multidrug-Resistant

2017